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Summary
Background The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly 
become the predominant lineage, owing to high transmissibility. It is suspected that the delta variant is associated 
with more severe disease than the previously dominant alpha (B.1.1.7) variant. We aimed to characterise the severity 
of the delta variant compared with the alpha variant by determining the relative risk of hospital attendance outcomes.
Methods This cohort study was done among all patients with COVID-19 in England between March 29 and 
May 23, 2021, who were identified as being infected with either the alpha or delta SARS-CoV-2 variant through whole-
genome sequencing. Individual-level data on these patients were linked to routine health-care datasets on vaccination, 
emergency care attendance, hospital admission, and mortality (data from Public Health England’s Second Generation 
Surveillance System and COVID-19-associated deaths dataset; the National Immunisation Management System; and 
NHS Digital Secondary Uses Services and Emergency Care Data Set). The risk for hospital admission and emergency 
care attendance were compared between patients with sequencing-confirmed delta and alpha variants for the whole 
cohort and by vaccination status subgroups. Stratified Cox regression was used to adjust for age, sex, ethnicity, 
deprivation, recent international travel, area of residence, calendar week, and vaccination status.
Findings Individual-level data on 43 338 COVID-19-positive patients (8682 with the delta variant, 34 656 with the alpha 
variant; median age 31 years [IQR 17–43]) were included in our analysis. 196 (2·3%) patients with the delta variant 
versus 764 (2·2%) patients with the alpha variant were admitted to hospital within 14 days after the specimen was 
taken (adjusted hazard ratio [HR] 2·26 [95% CI 1·32–3·89]). 498 (5·7%) patients with the delta variant versus 
1448 (4·2%) patients with the alpha variant were admitted to hospital or attended emergency care within 14 days 
(adjusted HR 1·45 [1·08–1·95]). Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for 
vaccinated patients with the delta variant versus the alpha variant (adjusted HR for hospital admission 1·94 [95% CI 
0·47–8·05] and for hospital admission or emergency care attendance 1·58 [0·69–3·61]) were similar to the HRs for 
unvaccinated patients (2·32 [1·29–4·16] and 1·43 [1·04–1·97]; p=0·82 for both) but the precision for the vaccinated 
subgroup was low.
Interpretation This large national study found a higher hospital admission or emergency care attendance risk for 
patients with COVID-19 infected with the delta variant compared with the alpha variant. Results suggest that 
outbreaks of the delta variant in unvaccinated populations might lead to a greater burden on health-care services than 
the alpha variant.
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Introduction
As SARS-CoV-2 evolves and new variants emerge 
worldwide, sustained monitoring and rapid assessment 
of genetic changes are required to inform the public 
health response and health-care management of 
COVID-19. WHO has outlined three key criteria to 
designate variants of concern (VOCs) in relation to global 
public health: increased transmissibility, increase in 
virulence or change in clinical disease presentation, 
and decrease in effectiveness of public health and social 
measures or available diagnostics, vaccines, and 
therapeutics.1
One of the first VOCs, alpha (B.1.1.7), was initially 
detected in England in November, 2020. Alpha had 
increased transmissibility compared with the previous 
wildtype lineage,2,3 and became the predominant lineage 
accounting for 95% of cases in England by early 
February, 2021.4 This variant has been identified in 
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154 countries and was until recently the most prevalent 
lineage in Europe and North America.5
The B.1.617 lineage was first reported in India 
in December, 2020.6,7 Following previous waves of 
COVID-19, the number of confirmed cases and test 
positivity in India rapidly increased, with the latter 
reaching 30% by the end of April, 2021.8 In Delhi, this 
coincided with the B.1.617 lineages overtaking the alpha 
lineage, accounting for 60% of all sequenced samples. 
During this increase, the sub-lineage delta (B.1.617.2) also 
increased to approximately 80% of B.1.617 cases.8
The delta variant was first detected in England in 
March, 2021, and was designated as a VOC on 
May 6, 2021.9 The proportion of COVID-19 cases in 
England caused by the delta variant has rapidly increased, 
reaching more than 50% of sequenced isolates by 
May 25, 2021.10 Studies in India have estimated that the 
delta variant could be up to 50% more transmissible than 
the alpha variant.8 In England, the secondary attack rate 
for the delta variant was found to be nearly 3%, compared 
with less than 2% for the alpha variant.10 In addition, 
there is evidence of modest reduction in vaccine 
effectiveness against infection with the delta variant.11 
However, among patients infected with the delta variant, 
previous vaccination has been reported to reduce the risk 
of hospital admission.12
To inform the public health response to the delta 
variant, we did two analyses. First, we characterised 
the severity of the delta variant compared with the 
alpha variant by determining the relative risk of hospital 
attendance or admission following infection using 
a stratified analysis. Second, we assessed whether 
associations with hospital attendance outcomes were 
modified by vaccination.
Methods
Data sources and definitions
This cohort study was done in England among 
individuals with laboratory confirmed COVID-19. 
COVID-19 is a notifiable disease and Public Health 
England collects data on all positive cases in England 
held within the Second Generation Surveillance System 
(SGSS).13,14 Individual-level data on patients with 
laboratory-confirmed COVID-19 with first positive 
specimen dates between March 29 and May 23, 2021, 
were linked with sequencing data uploaded to the Cloud 
Infrastructure for Big Data Microbial Bioinformatics 
database.15 Sampling for whole-genome sequencing 
mainly includes geographic-weighted population-level 
sampling of community cases, but can be supplemented 
by targeted selection such as recent international 
travellers, care homes, or National Health Service 
(NHS) diagnostic labo ratories.16 Variant classification 
was assigned on the basis of lineage definitions from 
Public Health England.17 Patients with whole-genome-
sequencing-confirmed alpha and delta variants were 
deterministically linked with data on vaccination,18 
hospital care,19,20 and mortality using NHS number.21 A 
full description of the data sources is in the appendix (p 1).
Potential cases of re-infection were removed to avoid 
misallocation of variants to different episodes of care 
by excluding observations for which the sequenced 
Research in context
Evidence before this study
We did a literature review to identify all publications on 
the severity of the SARS-CoV-2 delta variant (B.1.617.2). 
We searched PubMed on June 18, 2021, using the query: 
“((SARS-CoV-2) OR (COVID-19) OR (coronavirus disease 2019)) 
AND ((B.1.617.2) OR (Delta) OR (VOC-21APR-02)) AND ((severity) 
OR (hospitalisation) OR (hospital) OR (emergency care) OR 
(mortality) OR (lethality) OR (death))”. The search was restricted 
to articles published from Dec 1, 2020, with no language 
restrictions. Only one relevant publication was found. Based on 
record linkage of data on 7723 delta and 11 820 alpha variant 
COVID-19 cases between April 1 and June 6, 2021, with routine 
health-care data, the EAVE II study in Scotland reported a higher 
risk of hospital admission within 14 days for patients with the 
delta variant compared with the alpha variant (hazard ratio [HR] 
1·85 [95% CI 1·39–2·47). The patients had been tested through 
PCR tests and variant status was determined based on S-gene 
positivity, a proxy test for SARS-CoV-2 variant.
Added value of this study
This study included data on 8682 patients with the delta 
variant and 34 656 patients with the alpha variant, confirmed 
by whole-genome-sequencing. Hence, to our knowledge, it is 
the largest study to date to report on hospitalisation risk for the 
delta variant compared with the alpha variant, and the first to 
do so based on sequencing-confirmed variants. The HR of 
hospital admission within 14 days was 2·26 (95% CI 1·32–3·89) 
after stratification and regression adjustment for confounders. 
We also believe this study is the first to estimate a risk for 
emergency care attendance or hospital admission within 
14 days; the adjusted HR was 1·45 (1·08–1·95).
Implications of all the available evidence
The evidence from these two studies in Scotland and England 
consistently suggest that patients with COVID-19 who are 
infected with the delta variant have approximately two times the 
risk of hospital admission compared with patients with the alpha 
variant. These findings should be considered for resource and 
policy planning in secondary care, particularly in areas where the 
delta variant is increasing and is likely to become the dominant 
circulating SARS-CoV-2 variant.
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specimen collection date was more than 14 days after the 
specimen collection date of the individual’s first recorded 
positive test. Observations without an NHS number 
could not be linked to health-care datasets and were 
excluded.
The surveillance activities within which this study 
was conducted are part of Public Health England’s 
responsibility to monitor COVID-19 during the current 
pandemic. Public Health England has legal permission, 
provided by Regulation 3 of The Health Service (Control 
of Patient Information) Regulations 2002 to process 
confidential patient information under Sections 3(i) a–c, 
3(i) d(i and ii), and 3(iii) as part of its outbreak response 
activities. This study falls within the research activities 
approved by the Public Health England Research Ethics 
and Governance of Public Health Practice Group.
Hospital attendance categorisation
Hospital care data from the Emergency Care Data Set 
(ECDS) and Secondary Uses Service (SUS) were linked 
to data for patients with confirmed COVID-19 on 
June 7, 2021, thereby including data submitted by NHS 
Trusts up to June 5, 2021. Two outcomes of hospital 
attendance were defined: (1) hospital admission only, and 
(2) attendance to emergency care or hospital admission.
Due to a lag between an individual’s hospital admission 
and submission of corresponding SUS data (up to 
8 weeks), the definition of hospital admission was 
determined using a combination of ECDS and SUS 
variables, some of which exist in only one data source. 
Where ECDS data were available, hospital admissions 
were classified as COVID-19 related if a patient presented 
to emergency care between 1 and 14 days after the patient’s 
first SARS-CoV-2-positive specimen date, there was no 
International Classification of Disease version 10 (ICD10) 
code indicating that the attendance was injury related, and 
the discharge status indicated transfer or admission.
Where SUS data were available, hospital admissions 
were defined using two sets of criteria. The first set of 
criteria defined if the hospital visit was related to 
COVID-19 infection and the second evaluated whether 
the hospital visit qualified as an admission. All hospital 
visits for which the attendance date was between 1 and 
14 days after the first positive specimen date were 
considered COVID-19-related. If the admission date was 
the same as the specimen date, the visit was considered 
COVID-19 related if (1) the patient’s symptom onset date 
recorded in the laboratory system at the time of test was 
reported between 1–7 days before the specimen was 
taken, or (2) if hospital records included ICD10 codes 
relevant to COVID-19 and the patient died in hospital. 
These criteria add the flexibility of including records with 
evidence of onset preceding hospital attendance and 
severe COVID-19 related outcomes, without including 
coincidental hospitalisations among infected individuals. 
Admissions were defined as those where the interval 
between admission and discharge was more than 0 days; 
or if the interval between admission and discharge was 
0 days and either the hospital record included ICD10 
codes relevant to COVID-19 symptoms, or the patient 
died in hospital, or both.
Attendances to emergency care were included in the 
second hospital attendance outcome category. A patient 
was defined as having a COVID-19-related emergency 
care attendance if ECDS data indicated presentation to 
emergency care between 1 and 14 days after the patient’s 
first SARS-CoV-2-positive specimen date, there was no 
ICD10 code indicating that the attendance was injury-
related, and discharge details did not indicate transfer or 
admission.
Unless meeting the criteria described in this section, 
individuals who first tested positive on the same date 
as their hospital admission or attendance date were 
excluded to reduce bias of routine testing at admission 
for non-COVID-19 related attendances.
Covariates and confounders
Age, sex, and area of residence were extracted from SGSS 
for patients with COVID-19. National-level Index of 
Multiple Deprivation (IMD) quintile groups were 
matched to the patient’s lower super output area of 
residence. IMD is an area-level measure of relative 
socioeconomic deprivation. Ethnicity was determined 
from linkage to NHS England’s Hospital Episodes 
Statistics data and through self-reported ethnicity at the 
COVID-19 test request.
Recent travel was defined as a record of travel outside of 
the UK within 14 days before the patient’s positive 
COVID-19 test. This indicator was derived from five data 
sources: public health passenger locator forms, contact 
tracing of patients done by Public Health England 
and NHS Test and Trace, travel reported in the COVID-19 
test request form, records from the International 
Arrival COVID-19 testing programme, and additional 
questionnaires completed through telephone interview for 
patients for whom no other travel information was 
available.
Confounder sets were chosen for either stratification or 
regression adjustment on the basis of the expected 
strength of the association with exposure or outcomes. 
The initial outbreaks of the delta variant were localised to 
northern England and observed in south Asian ethnic 
groups, and increasing prevalence of the delta variant 
coincided with the expansion of the COVID-19 vacci-
nation programme to younger age groups.9,22 Therefore, 
the set of most likely confounders included age (10-year 
age bands),23 ethnicity (White; Asian; Black; and mixed, 
other, or unknown),24 calendar week of specimen, area of 
residence (lower tier local authority [LTLA]: 314 areas), 
and vaccination status.11
Additional potential confounders included sex and 
socioeconomic deprivation (IMD quintiles) due to 
association with hospitalisation risk,23,24 and international 
travel within 14 days of positive test, which was more 
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common for patients with the delta variant when its 
incidence first began to increase in England.9 There was no 
a-priori expectation that these variables would strongly 
confound the associations between variant and outcomes 
so they were considered for regression adjustment rather 
than stratification.
Statistical analysis
Patients were followed up for a maximum of 14 days from 
their earliest COVID-19-positive specimen until the 
hospital admission or emergency care attendance date. 
Patients were censored at the date of death if this occurred 
without a previous hospital attendance event within the 
14-day period.
In the primary analysis, stratified Cox regression was 
used to estimate hazard ratios (HRs) of the hospitalisation 
outcomes (hospital admission or emergency care atten-
dance) for patients with the delta variant compared with 
patients with the alpha variant. Strata were created by 
intersecting the likely confounders. Additional potential 
confounders were included using main effects. Linear 
main effects terms for age and calendar date were used to 
adjust for residual confounding after stratification.
In the secondary analysis, the HRs of the hospi-
talisation outcomes by variant were estimated by 
vaccination status. The base models were refitted with an 
interaction term between variant and vaccination. Due to 
low numbers of patients with COVID-19 who had been 
vaccinated, and consequently low numbers within some 
vaccination categories, vaccination status was grouped 
into two categories: unvaccinated or less than 21 days 
since the first vaccination dose; and 21 days or more 
since the first vaccination dose, with or without the 
second dose.
In additional analyses, the proportional hazards assum-
ption of the Cox regression model was graphically assessed 
using Schoenfeld residual plots and formally tested using 
the Schoenfeld test. Post-evaluations of the relative 
magnitudes of the confounders’ contribution to the adjusted 
HRs were done by sequentially adding the adjustment 
variables in the order of the percentage change in the 
adjusted HRs for patients with the delta variant versus the 
alpha variant. To assess the impact of stratification versus 
regression modelling on the HRs and 95% CIs, the primary 
model was refitted with each stratification variable instead 
included as a regression variable.
HRs were assessed for sensitivity to stratification by 
alternative region or calendar period covariates, con-
founding due to recent international travel or symptomatic 
status subgroups, or to the precise outcome definitions. 
Details are shown in the appendix (p 8).
Data were prepared using Stata version 15.1. Statistical 
analyses were done in R version 4.1.0.
Role of the funding source
The funders of the study had no role in study 
design, data collection, data analysis, data interpretation, 
writing of the report, or in the decision to submit for 
publication.
Results
Of the 49 930 sequencing-confirmed cases of alpha and 
delta variants in England from March 29 to May 23, 2021, 
43 338 were included in our analysis (appendix p 2). 
5634 records were excluded due to missing NHS numbers 
(4240 [10·7%] of 39 677 patients with the alpha variant and 
1394 [13·6%] of 10 253 patients with the delta variant). 
Missing NHS number occurred more frequently among 
Black and Asian individuals than White individuals 
(1512 [15·0%] of 10 075 Asian, 291 [19·3%] of 1508 Black, 
and 2574 [7·7%] of 33 306 White individuals), and among 
international travellers (871 [29·5%] of 2952 international 
travellers vs 4762 [10·1%] of 46 977 non-travellers).
34 656 patients were infected with the alpha variant and 
8682 patients had the delta variant; the proportion of 
weekly cases by variant changed across the study period 
with alpha decreasing from 7593 (99·8%) of 7606 cases 
in the week of March 29, 2021, to 2117 (34·8%) of 
6090 cases in the week of May 17, 2021. Patients with the 
delta variant were younger (median age 29 years 
[IQR 15–41]) than patients with the alpha variant (median 
age 31 years [17–43]). Compared with patients with the 
alpha variant, a greater proportion of patients with the 
delta variant were from an Asian background, or lived in 
the north west of England or London (table 1).
The results of the analysis of hospital attendance 
outcomes among patients with the alpha variant versus 
the delta variant are shown in table 2. The estimated risk 
for hospital admission within 14 days after the specimen 
was taken was higher among patients with the delta 
variant than the alpha variant. The estimated risk for 
hospital admission or emergency care within 14 days was 
also higher among patients with the delta variant than 
the alpha variant.
Table 3 shows the HRs of the hospital attendance 
outcomes for patients with the delta variant versus the 
alpha variant by vaccination status. Among patients who 
were unvaccinated or had less than 21 days since the 
first vaccination dose, patients with the delta variant had a 
higher estimated risk of hospital admission and a 
higher risk of either hospital admission or emergency 
care attendance than patients with the alpha variant. In 
the subgroup of vaccinated patients (≥21 days after first 
vaccination dose, with and without a second dose), no 
significant difference was detected in the estimated risk 
for either hospital attendance outcome between patients 
with the delta variant and patients with the alpha variant. 
The risk estimates for the delta versus the alpha variant 
among vaccinated patients were limited by low precision 
and wide CIs. There were no significant interactions 
when comparing the HRs in the vaccinated versus 
unvaccinated subgroups (table 3).
The Schoenfeld residuals and test showed no 
significant deviation from the proportional hazards 
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assumption (appendix p 3). The post-evaluations of the 
confounders showed that adjusted HRs of both categories 
of hospital attendance outcome (hospital admission, 
hospital admission or emergency care attendance) 
changed the most when adjusted for calendar week 
(83% change for hospital admission, 39% change for 
hospital admission or emergency care attendance; 
appendix p 4). When including one or all stratification 
variables as regression variables instead, the estimated 
risk for both hospital attendance outcomes were 
consistently greater for patients with the delta variant 
than for patients with the alpha variant (appendix p 7). 
The sensitivity analyses in which the impact on the 
results was assessed after adjustment for alternative 
region or calendar period variables, symptomatic status, 
analyses of subgroups, or after varying the outcome 
definitions are shown in the appendix (pp 8–9). The 
estimated risk for both categories of hospital attendance 
outcomes was higher for patients with the delta variant 
than for patients with the alpha variant in all sensitivity 
analyses. The differences were consistently statistically 
significant, except the subgroup analysis by symptom 
status, in which the CIs were wider, and in some 
instances included 1.
Discussion
New SARS-CoV-2 infections in England are increasingly 
caused by the delta variant. Although the proportion of 
cases caused by the delta variant was 20% overall during 
the study period, this increased to 74% of new sequenced 
cases in the week starting May 31, 2021.9 To our 
knowledge, this study provides the largest whole-genome-
sequencing dataset for SARS-CoV-2 in a high-income 
country to date, enabling the assessment of hospitalisation 
risk for the delta variant compared with the alpha variant 
using linked administrative data. The results suggest that 
patients with the delta variant had more than two times 
the risk of hospital admission compared with patients 
with the alpha variant. Emergency care attendance 
combined with hospital admission was also higher 
for patients with the delta variant, showing increased use 
of emergency care services as well as inpatient 
hospitalisation. Similar results were observed for the 
subgroup of unvaccinated patients when comparing risks 
of both hospital care outcomes between the two variants. 
In the subgroup of patients who had received at least one 
vaccine dose (≥21 days since their first dose), the precision 
was too low to determine whether the risks of the 
outcomes were higher or similar for patients with the 
delta variant compared with patients with the alpha 
variant. It has previously been reported that vaccination 
leads to a similar relative reduction in the risk of 
hospitalisation for patients with the delta variant or the 
alpha variant.12 This is consistent with the findings in the 
present study: overall, the number of hospital attendances 
were low in the vaccinated subgroup resulting in low-








<10 3564 (8·2%) 2671 (7·7%) 893 (10·3%)
10–19 9462 (21·8%) 7373 (21·3%) 2089 (24·1%)
20–29 7636 (17·6%) 6183 (17·8%) 1453 (16·7%)
30–39 9157 (21·1%) 7364 (21·2%) 1793 (20·7%)
40–49 6885 (15·9%) 5588 (16·1%) 1297 (14·9%)
50–59 3916 (9·0%) 3196 (9·2%) 720 (8·3%)
60–69 1681 (3·9%) 1375 (4·0%) 306 (3·5%)
70–79 584 (1·3%) 495 (1·4%) 89 (1·0%)
≥80 453 (1·0%) 411 (1·2%) 42 (0·5%)
Sex
Female 22 162 (51·1%) 17 913 (51·7%) 4249 (48·9%)
Male 21 176 (48·9%) 16 743 (48·3%) 4433 (51·1%)
Ethnicity
White 30 152 (69·6%) 25 940 (74·8%) 4212 (48·5%)
Black 1183 (2·7%) 854 (2·5%) 329 (3·8%)
Asian 8416 (19·4%) 5130 (14·8%) 3286 (37·8%)
Mixed, other, or unknown 3587 (8·3%) 2732 (7·9%) 855 (9·8%)
Region of residence within England
London 3854 (8·9%) 2601 (7·5%) 1253 (14·4%)
East midlands 5021 (11·6%) 4309 (12·4%) 712 (8·2%)
East of England 3808 (8·8%) 2771 (8·0%) 1037 (11·9%)
North east 2519 (5·8%) 2385 (6·9%) 134 (1·5%)
North west 10 561 (24·4%) 6354 (18·3%) 4207 (48·5%)
South east 2381 (5·5%) 1933 (5·6%) 448 (5·2%)
South west 723 (1·7%) 573 (1·7%) 150 (1·7%)
West midlands 4135 (9·5%) 3645 (10·5%) 490 (5·6%)
Yorkshire and Humber 10 336 (23·8%) 10 085 (29·1%) 251 (2·9%)
Index of multiple deprivation, quintile*
1 14 480 (33·4%) 11 476 (33·1%) 3004 (34·6%)
2 9474 (21·9%) 7517 (21·7%) 1957 (22·5%)
3 7326 (16·9%) 5997 (17·3%) 1329 (15·3%)
4 6737 (15·5%) 5413 (15·6%) 1324 (15·2%)
5 5321 (12·3%) 4253 (12·3%) 1068 (12·3%)
Calendar week of specimen in 2021
March 29–April 4 7606 (17·6%) 7593 (21·9%) 13 (0·1%)
April 5–April 11 5635 (13·0%) 5568 (16·1%) 67 (0·8%)
April 12–April 18 4806 (11·1%) 4673 (13·5%) 133 (1·5%)
April 19–April 25 4774 (11·0%) 4431 (12·8%) 343 (4·0%)
April 26–May 2 4690 (10·8%) 4058 (11·7%) 632 (7·3%)
May 3–May 9 4985 (11·5%) 3608 (10·4%) 1377 (15·9%)
May 10–May 16 4752 (11·0%) 2608 (7·5%) 2144 (24·7%)
May 17–May 23 6090 (14·1%) 2117 (6·1%) 3973 (45·8%)
Vaccination status at date of specimen
Unvaccinated 32 078 (74·0%) 25 823 (74·5%) 6255 (72·0%)
<21 days after first vaccination dose 2632 (6·1%) 2206 (6·4%) 426 (4·9%)
≥21 days after first vaccination dose 7834 (18·1%) 6172 (17·8%) 1662 (19·1%)
≥14 days after second vaccination dose 794 (1·8%) 455 (1·3%) 339 (3·9%)
Recent international travel within 14 days before specimen
No 41 435 (95·6%) 33 218 (95·9%) 8217 (94·6%)
Yes 1903 (4·4%) 1438 (4·1%) 465 (5·4%)
(Table 1 continues on next page)
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This analysis is strengthened by using national, timely 
datasets on COVID-19 cases, hospital care episodes, 
and vaccinations. The individual-level data included all 
laboratory-confirmed COVID-19 cases, up to 98% of 
hospital activity, and all vaccinated individuals registered 
with a general practitioner in England,14,18,25 with these 
data updated daily. Whole-genome sequencing coverage 
in England increased throughout the study period: for 
new positive tests between April 23 and May 24, 2021, 
more than 60% were successfully sequenced.9
Compared with a matched study design, the stratified 
Cox regression method offers the advantage of using all 
potential matches rather than a fixed number of patients 
with the alpha variant per patient with the delta variant. 
Confounders such as changing demographic profiles of 
patients by variant or local interventions over time are 
accounted for. However, this method results in a loss of 
informative observations when stratifying by many 
covariates, reducing precision compared with estimates 
based on adjustment through regression modelling.
Administrative data have several limitations in this 
context. First, hospital admission data received via SUS 
can have a reporting delay due to monthly submission 
periods, which could lead to confounding. This delay and 
potential confounding was mitigated by both using more 
rapid ECDS data to identify hospital admissions via 
presentation to emergency care and stratification by 
calendar time. The confounder post-evaluation found 
that the HRs were most changed by adjustment for 
calendar week, indicating that the unadjusted estimates 
were indeed confounded by registration delays or other 
calendar-period-specific factors. Also, given regression 
adjustment on specific calendar date, residual con-
founding due to registration delays seems unlikely and is 
expected to affect the more recent delta cases primarily, 
causing a slight underestimation of the HRs. Second, 
there was suboptimal information on the reason for 
a hospital visit, preventing conclusive attribution of 
attendance or admission to COVID-19. However, some 
data flags such as injury-related attendance and ICD10 
codes were used as proxies to define outcomes in the 
primary analysis. Nevertheless, non-COVID-19-related 
visits might have been included, resulting in a slight 
underestimate of the HRs because this misclassification 
is not expected to differ by variant. A strength of 
considering alternative outcomes is that different 
categories of hospital use, which could indicate levels of 
disease severity, have been assessed; these sensitivity 
analyses showed some variation in HRs but estimated 
risks were consistently higher for patients with the delta 
variant than with the alpha variant. Finally, there were no 
available data on comorbidities, which are known to 
contribute to hospitalisation risk.24 This study instead 
indirectly accounted for comorbidities using related 
covariates, including age, sex, ethnicity, and deprivation.26
Linkage was not possible for all sequenced cases 
due to missing NHS numbers. 5634 (11·3%) of 
49 930 sequenced cases during the study period were 
excluded for this reason. International travellers and 
minority ethnic groups were overrepresented among 
patients with missing NHS numbers. These groups were 







(Continued from previous page)
Symptom status at the time of specimen
Asymptomatic 18 593 (42·9%) 14 934 (43·1%) 3659 (42·1%)
Symptomatic 22 091 (51·0%) 17 757 (51·2%) 4334 (49·9%)
Unknown 2654 (6·1%) 1965 (5·7%) 689 (7·9%)
Data are n (%). *Quintiles are ranked from most deprived (quintile 1) to least deprived (quintile 5).





HR (95% CI), delta variant vs alpha 
variant
Unadjusted Adjusted*
Hospital admission within 
14 days after specimen
764/34 656 (2·2%) 196/8682 (2·3%) 1·03 (0·88–1·21) 2·26 (1·32–3·89)
Hospital admission or 
emergency care 
attendance within 
14 days after specimen
1448/34 656 (4·2%) 498/8682 (5·7%) 1·39 (1·25–1·53) 1·45 (1·08–1·95)
Data are n/N (%) except where otherwise stated. HR=hazard ratio. *Stratification for age group, ethnicity, lower-tier 
local authority, calendar week of specimen, vaccination status; regression adjustment for age (linear), date (linear), 
sex, index of multiple deprivation, and international traveller status.
Table 2: Hospitalisation outcomes for patients with the delta variant compared with patients with the 
alpha variant
Alpha variant* Delta variant* Adjusted HR (95% CI)†, 





<21 days after first 
vaccination dose
536/28 029 (1·9%) 149/6681 (2·2%) 2·32 (1·29–4·16) ··
≥21 days after first 
vaccination dose with or 
without second 
vaccination dose
228/6627 (3·4%) 47/2001 (2·3%) 1·94 (0·47–8·05) 0·82
Hospital admission or emergency care attendance
Unvaccinated or 
<21 days after first 
vaccination dose
1095/28 029 (3·9%) 369/6681 (5·5%) 1·43 (1·04–1·97) ··
≥21 days after first 
vaccination dose with or 
without second 
vaccination dose
353/6627 (5·3%) 129/2001 (6·4%) 1·58 (0·69–3·61) 0·82
Data are n/N (%) except where otherwise stated. HR=hazard ratio. *These crude descriptive frequencies are unadjusted 
for age and other confounders, and so they are not directly comparable between the groups. †Stratification for age 
group, ethnicity, lower-tier local authority, calendar week, vaccination status; regression adjustment for age, sex, index 
of multiple deprivation, specimen date, and international travel status. ‡p values are for tests for interaction between 
vaccination status and variant.
Table 3: Hospitalisation outcomes for patients with the delta variant compared with patients with the 
alpha variant, by vaccination status
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with the alpha variant group. Although there are no data 
to suggest that the hospital attendance or admission risk 
would systematically differ for the excluded individuals 
compared with their included peers, this cannot be 
ruled out.
Hospital use and admission risk might be influenced 
by heterogenous health-care-seeking behaviour and 
transmission across the variants, ethnic groups, and 
particularly over time and area. Changes over time in 
hospital admission policy might have occurred—eg, due 
to local hospital burden or increased use of at-home 
pulse oximeter monitoring.27 Such changes might have 
resulted in reduced length of stay, with shorter stays less 
affected by reporting delays in more recent weeks. 
However, stratification for calendar week and area of 
residence should account for such differences.
The conditions for whole-genome-sequencing selection 
and successful sequencing might restrict the 
generalisability of the study findings. Samples that test 
positive by PCR are most likely to be successfully 
sequenced if they have a low enough cycle threshold 
value (<30), which might be more likely in patients with a 
high viral load. In addition, when comparing sequenced 
and non-sequenced samples in the study period, there 
was an overrepresentation in sequenced samples from 
patients in younger age groups and from areas in 
northern England. This is likely to be due to geographic 
area-based increases in sequencing to understand the 
initial outbreaks of the delta variant. There was also a 
higher proportion of pillar 2 (ie, community-based) 
samples that were sequenced compared with samples 
taken through pillar 1 (public health and hospital testing 
and routine screening).28 Despite the potential that a 
higher proportion of delta variant samples might have 
been sequenced due to increased regional coverage, 
slightly higher ascertainment is not likely to have 
significantly reduced detection of the alpha variant 
because alpha was the most prevalent variant throughout 
March and April, 2021. The same sequence-quality 
metrics were also applied across all samples and the area-
level sampling would have included a mixture 
of individuals with the alpha variant and individuals 
with the delta variant. There was no expected sample 
prioritisation by variant based on clinical status, 
particularly as most sequenced samples were from 
community testing.
During the study period, the incidence of the delta 
variant in England was increasing, and so individuals 
with shorter times from infection to positive test (ie, more 
recent infections) might be overrepresented among 
those who tested positive. By contrast, the incidence of 
the alpha variant was decreasing during the study period, 
and so individuals with longer times to positive test 
(ie, less recent infections) are likely to be overrepresented.29 
Time from infection to testing positive among the 
patients in this study might be dependent on symptoms 
that prompt someone to be tested, because most the 
study population had community (pillar 2) testing, rather 
than routine testing in hospital or for screening (pillar 1). 
People who test quickly might be more likely to have 
earlier or more symptoms than people who test less 
quickly, suggesting that their disease progression might 
have been both faster and more severe. This differential 
selection of patients with potentially more severe 
symptoms from the delta variant and patients with less 
severe symptoms from the alpha variant might result in 
an overestimation of the HRs. However, this bias might 
be mitigated by the overall preferential selection of 
patients with low cycle threshold values (higher viral 
load), that might affect the alpha and delta variant groups 
similarly. Furthermore, the estimated HRs were similar 
for patients who were asymptomatic at the time the 
specimen was taken, for whom the time from infection 
to test is unlikely to reflect differences in test-seeking 
behaviour. To address this bias, incidence would need to 
be modelled jointly with severity.
The impact of the delta variant within India has been 
substantial. Alongside high infection incidence, major 
cities also experienced overwhelming hospital burden 
leading to shortages of supplies and life-saving 
equipment.6 However, there has been little research done 
to quantify the hospitalisation risk for patients with this 
variant. The EAVE II study is a recent, large-scale study 
reporting on the hospital admission risk for patients with 
the delta variant in Scotland.30 Based on record-linkage of 
routine health-care data, it used S-gene target detection 
through diagnostic tests as a proxy for delta compared 
with the alpha profile that includes S-gene target failure. 
Their results showed an adjusted HR of hospital 
admission of 1·85 (95% CI 1·39–2·47), which is 
consistent with the HR of 2·26 (1·32–3·89) estimated in 
this study.
Supplementary sensitivity analyses provide assurance 
regarding the robustness of outcomes; however, future 
work should include metrics based on richer but less 
timely data on severe COVID-19 outcomes, such as 
length of hospital stay, admission to intensive care, or 
indicators of critical illness. Further work is also needed 
to measure the risk of mortality due to the delta variant, 
as a large proportion of the cohort included in this study 
was still within the 28-day follow-up period when analysis 
was done.
To our knowledge, this study is the largest assessment 
of hospitalisation risk for the delta variant using cases 
confirmed by whole-genome sequencing, providing 
important foundational evidence of increased risk 
compared with the alpha variant. Before the emergence 
of the delta variant, the evidence base largely focused on 
the alpha variant and its higher transmissibility 
and severity when compared with previous wildtype 
strains.2,3,31–33 Further research is needed to clarify if the 
hospitalisation risks differ in vaccinated individuals 
infected with the delta variant compared with the alpha 
variant; however, a previous study has estimated low 
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hospitalisation risks for vaccinated individuals after 
infection with either variant.12 Together, these two studies 
suggest that outbreaks of the delta variant in unvaccinated 
populations might lead to a higher health-care burden, 
particularly compared with the previous prevalent 
SARS-CoV-2 strains. The findings are key for resource 
planning and policy decisions to mitigate the impact of 
the delta variant in the UK, where the delta variant now 
dominates, and in other high-income countries where the 
rapid spread of the delta variant might occur.
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